Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nt to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
Stammdaten
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Unternehmen & Branche
| Name | Instil Bio, Inc. |
|---|---|
| Ticker | TIL |
| CIK | 0001789769 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 55,9 Mio. USD |
| Beta | 2,03 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -71,372,000 | -10.70 | 203,523,000 | 113,866,000 | |
| 2025-09-30 | 10-Q | -13,587,000 | -2.01 | 211,768,000 | 120,422,000 | |
| 2025-06-30 | 10-Q | -21,394,000 | -3.24 | 230,986,000 | 131,670,000 | |
| 2025-03-31 | 10-Q | -28,200,000 | -4.32 | 237,449,000 | 144,912,000 | |
| 2024-12-31 | 10-K | -74,135,000 | -11.39 | 263,567,000 | 169,436,000 | |
| 2024-09-30 | 10-Q | -23,021,000 | -3.54 | 272,562,000 | 176,332,000 | |
| 2024-06-30 | 10-Q | -14,917,000 | -2.29 | 294,316,000 | 195,019,000 | |
| 2024-03-31 | 10-Q | -24,302,000 | -3.74 | 306,303,000 | 205,827,000 | |
| 2023-12-31 | 10-K | -156,087,000 | -24.00 | 325,630,000 | 225,829,000 | |
| 2023-09-30 | 10-Q | -67,432,000 | -10.37 | 340,272,000 | 234,024,000 | |
| 2023-06-30 | 10-Q | -18,662,000 | -2.87 | 408,310,000 | 296,516,000 | |
| 2023-03-31 | 10-Q | -57,068,000 | -8.77 | 427,172,000 | 311,154,000 | |
| 2022-12-31 | 10-K | -223,177,000 | -34.46 | 482,128,000 | 363,605,000 | |
| 2022-09-30 | 10-Q | -56,224,000 | -0.43 | 532,741,000 | 410,588,000 | |
| 2022-06-30 | 10-Q | -58,992,000 | -0.46 | 568,536,000 | 458,332,000 | |
| 2022-03-31 | 10-Q | -54,117,000 | -0.42 | 564,936,000 | 508,559,000 | |
| 2021-12-31 | 10-K | 0 | -156,794,000 | -1.48 | 609,983,000 | 555,199,000 |
| 2021-09-30 | 10-Q | 0 | -43,005,000 | -0.33 | 647,397,000 | 601,420,000 |
| 2021-06-30 | 10-Q | 0 | -35,311,000 | -0.27 | 672,670,000 | 635,472,000 |
| 2021-03-31 | 10-Q | 0 | -23,128,000 | -0.66 | 696,142,000 | 665,153,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-09-10 | Laumas Sandeep | Officer, CFO and CBO | Open Market Sale | -12,461 | 23.88 | -297,568.68 | -84,8% | |
| 2025-09-10 | Laumas Sandeep | Officer, CFO and CBO | Open Market Sale | -17,539 | 23.04 | -404,098.56 | -115,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.